Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') today announced that the first patient has been dosed in a Phase II clinical study (AK146D1-201) evaluating its internally developed TROP2/Nectin-4 ...

Eighteen companies have gone public this year so far, putting 2026 on pace to record the highest number of IPOs since the ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. ("“Regeneron” or the “Company”) (NASDAQ: REGN) and reminds ...

E-bike injuries are increasing across California, according to a new study. Injured riders are often 14 or younger.

The risk of hair loss in patients taking GLP-1 drugs for obesity or diabetes, while low, is higher than with other diabetes ...

The Delhi High Court has observed that students who spend “hours and months” preparing for admission to premier institutions ...

A 2026 BMJ study found GLP-1 drugs like Ozempic carry a 37–68% higher alopecia risk vs. other diabetes medications. The post ...

ACTiVION-II, the first of two US Phase 3 clinical trials, did not meet co-primary endpoints of VAS pain score and WOMAC® total score at Month 12Results from ACTiVION-I, the second Phase 3 trial of ...

A mom who returned to university in her 60s has graduated alongside her daughter after years of late-night study sessions ...

It started as a routine phonics lesson in the 1st grade Bronx classroom I was observing to study how students learn to read.

Emergency physicians say the growing popularity of high-speed electric bikes is fueling a rise in serious pediatric injuries.

Here may be a case-study in how fraught building new housing can be in a city known for its stubborn resistance to change and ...